INTRODUCTION
Overactivation of mineralocorticoid receptor pathways in choroidal vessels have been noted in experimental models of central serous chorioretinopathy (CSCR) [1] . [5] . A subset of patients appear to have persistent subretinal fluid in the absence of persistent intraretinal fluid, and this has been described as a ''secondary sick RPE syndrome'' [6] . Photodynamic therapy (PDT) has been described as successful in some of these cases, even in the absence of any identification of polypoidal choroidal vasculopathy or true CSCR [6] .
No satisfactory treatment modality has been described for these cases of neovascular AMD refractory to anti-VEGF treatment [7] . The purpose of this study was to evaluate the efficacy of eplerenone as an adjunctive treatment in cases of neovascular AMD with refractory subretinal fluid.
METHODS
This was a retrospective study conducted at a single center with two retinal surgeons with IRB approval. Patients were included in the study if they had a previous diagnosis of neovascular An overall optimal response was noted in patients that had a shaggy photoreceptor outer layer, were pachychoroid for age, and had an absence of moderate-large pigment epithelial detachments. 8 of the 13 patients in group B had all these characteristics. In this subgroup, mean initial CMT was 319.4 lm and mean final CMT was 236.1 lm. The mean initial injection interval was 39.5 days and the mean final injection interval was 60.7 days (p\0.05), for a mean extension of the injection interval in this group of 21.2 days.
Two cases are presented of patients from group B. Case 1 (Fig. 1a-e) Case 2 (Fig. 2a-e) was an 80-year-old female.
She initially presented with significant CME and SRF with a BCVA of 20/150. After three months of bevacizumab, all the CME had resolved, and vision had improved to 20/80, but she had persistent subretinal fluid and a shaggy photoreceptor outer layer, so she was switched to aflibercept. After 6 months of This anatomic overlay begs the question of whether a deeper overlap of wet AMD and CSCR exists in some patients than previously realized.
The demographic breakdown in the present study does not classically point to one typical of patients with CSCR, given a relatively equivalent breakdown of sex and a mean age that is much higher than average for CSCR. We also did not find evidence of a true sick RPE syndrome in these patients, as initial or repeat ICG did not show evidence of a true diffusely abnormal choroidal circulation. It is possible that these patients develop a secondary focal reactive RPE dysfunction that leads to a CSCR-type response.
Limitations of this study include its retrospective nature and the limitation of our ability to make inferences until a randomized controlled trial is completed. 
